1-hexadecyl-2-acetyl-glycero-3-phosphocholine has been researched along with Anti-Phospholipid Antibody Syndrome in 6 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 5 (83.33) | 18.2507 |
| 2000's | 1 (16.67) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Adams, DM; Peaceman, AM; Silver, RK | 1 |
| Barquinero, J; Khamashta, M; Ordi-Ros, J; Perez-Peman, P; Selva, A; Vilardell, M | 1 |
| Caplan, MS; O'Connell, PD; Silver, RK | 1 |
| Ioannidis, JP; Moutsopoulos, HM; Petrovas, CA; Tektonidou, MG; Vlachoyiannopoulos, PG | 1 |
| Ben-Bassat, M; Blank, M; Krause, I; Shoenfeld, Y | 1 |
| Adler, L; Hageman, JR; Hickman, AR; Silver, RK | 1 |
1 review(s) available for 1-hexadecyl-2-acetyl-glycero-3-phosphocholine and Anti-Phospholipid Antibody Syndrome
| Article | Year |
|---|---|
Understanding prostaglandin metabolites and platelet-activating factor in the pathophysiology and treatment of the antiphospholipid syndrome.
Topics: Abortion, Habitual; Antiphospholipid Syndrome; Aspirin; Female; Humans; Platelet Activating Factor; Pregnancy; Prostaglandin Antagonists; Prostaglandins | 1995 |
5 other study(ies) available for 1-hexadecyl-2-acetyl-glycero-3-phosphocholine and Anti-Phospholipid Antibody Syndrome
| Article | Year |
|---|---|
Antibodies against platelet-activating factor in patients with antiphospholipid antibodies.
Topics: Antibodies, Antiphospholipid; Antibody Specificity; Antiphospholipid Syndrome; Autoantibodies; Humans; Lupus Coagulation Inhibitor; Lupus Erythematosus, Systemic; Platelet Activating Factor; Syphilis | 1994 |
Acetylsalicylic acid inhibits anticardiolipin antibody-induced platelet-activating factor (PAF) synthesis.
Topics: Antibodies, Anticardiolipin; Antiphospholipid Syndrome; Aspirin; Cells, Cultured; Dose-Response Relationship, Drug; Endothelium, Vascular; Epoprostenol; Female; Humans; Hydrogen-Ion Concentration; Platelet Activating Factor; Pregnancy; Pregnancy Complications | 1993 |
Clinical importance of antibodies against platelet activating factor in antiphospholipid syndrome manifestations.
Topics: Adult; Aged; Antibodies, Anticardiolipin; Antibody Specificity; Antiphospholipid Syndrome; beta 2-Glycoprotein I; Enzyme-Linked Immunosorbent Assay; Female; Glycoproteins; Humans; Immunoglobulin G; Immunoglobulin M; Male; Middle Aged; Odds Ratio; Phosphatidylcholines; Platelet Activating Factor; Scleroderma, Systemic; Seroepidemiologic Studies; Thrombosis | 2000 |
Induction of experimental anti-phospholipid syndrome associated with SLE following immunization with human monoclonal pathogenic anti-DNA idiotype.
Topics: Animals; Antibodies, Anticardiolipin; Antibodies, Antinuclear; Antiphospholipid Syndrome; Body Weight; Cross Reactions; Disease Models, Animal; Female; Fetal Resorption; Lupus Erythematosus, Systemic; Mice; Mice, Inbred BALB C; Organ Size; Phospholipids; Placenta; Platelet Activating Factor; Pregnancy; Pregnancy Complications; Pregnancy Outcome; Vaccination | 1992 |
Anticardiolipin antibody-positive serum enhances endothelial cell platelet-activating factor production.
Topics: 6-Ketoprostaglandin F1 alpha; Antibodies; Antiphospholipid Syndrome; Calcimycin; Cardiolipins; Dose-Response Relationship, Drug; Endothelium, Vascular; Humans; Platelet Activating Factor; Umbilical Veins | 1991 |